Skip to main content
Report this ad

See also:

CytoDyn Inc: New Hope for HIV

CytoDyn Inc. (OTCQB:CYDY) Aims to Offer a New Treatment Paradigm for HIV Patients
HIV awareness continues to remain at the forefront of the healthcare industry in the United States and across the globe. Medical doctors and researchers around the world are diligently seeking to develop successful alternatives to the current HIV treatment options available on the market. Unfortunately, due to time requirements for research and development, patent policies and procedures, and the FDA approval process, the road to optimum treatment has been a long one. Patients infected with the Human Immunodeficiency Virus have not seen a significant change in standard treatment methods in years. Fortunately, change is forthcoming thanks to CytoDyn Inc., a publicly traded biotechnology company with the mission of creating new treatment therapies to combat immune deficiency viruses, namely HIV.

CytoDyn’s Lead Product Candidate
PRO 140, a humanized monoclonal antibody, is CytoDyn’s leading HIV treatment candidate. It is part of a relatively new class of HIV and AIDs therapeutics known as viral-entry inhibitors, that are intended to guard healthy cells against viral infection. They function by blocking HIV access to the molecular portal CCR5, the point of cellular entry for viruses. The results from Phases 1/1b and 2a human clinical trials are impressive, indicating that PRO 140 is capable of significantly reducing the viral load of HIV patients without affecting the normal function of the cell.

These results can lead to major breakthroughs in the future of HIV treatment, setting CytoDyn apart from its top competitors, such as Gilead Sciences. While Gilead offers a variety of HIV drugs and has reduced the number of pills patients need to take, the medications must be taken daily and patients have to deal with recurring and sometimes serious side-effects. In comparison, PRO 140 antibody is not a drug and has no toxicity profile. PRO 140 has a milder side-effect profile and less frequent dosing requirements – weekly or bimonthly are anticipated.

FDA Approves Further Research
CytoDyn recently announced that it has received approval from the FDA to move ahead with its research on PRO 140. The Phase 2b study is being conducted by Drexel University College of Medicine. Cytodyn is collaborating with Dr. Jeffrey M. Jacobson, Professor of Infectious Disease and HIV Specialist at Drexel University College of Medicine, who directed the initial trial development for PRO 140. The study will be funded by grants from the National Institutes of Health.

Invest in CytoDyn
The need for HIV therapies has remained consistent and the demand for a broader spectrum of treatment options continues to increase. The results of the research on PRO 140 could be the key to overhauling HIV treatment around the world and establishing a solid foundation for additional research. Dr. Nader Pourhassan, President and CEO of CytoDyn, believes that the company is in a position to become the next leader in the development of monoclonal antibody therapy to treat and prevent HIV and AIDS. Investors seeking to get involved in this exciting venture can learn more by visiting the CytoDyn website.

Report this ad